Compare AstraZeneca plc (AZN) vs iShares MSCI South Africa ETF (EZA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs iShares MSCI South Africa ETF — how do they compare? AstraZeneca plc trades at $159.07 (market cap $250.84B), while iShares MSCI South Africa ETF trades at $68.5. The key difference: AstraZeneca plc pays a 1.97% dividend while iShares MSCI South Africa ETF pays none, and iShares MSCI South Africa ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | EZA | |
|---|---|---|
Market Cap | $250.84B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $209.48 | $81.60 |
52-Week Low | $147.06 | $56.36 |
Enterprise Value | $278.12B | — |
Dividend Yield | 1.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.42, up 0.22% today, amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth to $58.74B in 2025 and net income of $10.23B, supported by a P/E of 24.16 and robust profitability margins. Recent news highlights potential talks with Bristol Myers Squibb, though a senior source denied ongoing discussions (Reuters, 2026-08-05).
The outlook is mixed: solid earnings beats and a 47.5% analyst buy rating support upside, but technical weakness and merger uncertainty pose near-term risks. Long-term growth hinges on execution amid competitive and regulatory pressures, with the stock offering value if merger rumors subside and fundamentals prevail.
EZA trades at $69.65, up 4.14% today, with a bullish technical signal from moving averages but overbought oscillators. The stock faces resistance near $68 and support at $66. Recent news highlights macroeconomic pressures on its South African-focused portfolio, including exposure to gold, banking, and platinum group metals amid rising interest rates and inflation.
The outlook is mixed, with technical strength offset by fundamental headwinds from global reflation. Investment opportunities hinge on commodity price stability, while risks include yield curve dynamics and cost of capital increases that may pressure constituent earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About iShares MSCI South Africa ETF
EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.
Read more on EZA →
